Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1181

Enrollment

INDUSTRY

Sponsor class

Conditions

Transthyretin Amyloid Cardiomyopathy

Interventions

DRUG: ALXN2220
DRUG: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.